Skip to main content
. 2016 May 6;7(24):36255–36265. doi: 10.18632/oncotarget.9199

Figure 5. TAZ enhances the activity of the EGFR/AKT/ERK pathway.

Figure 5

(A) The expression of p-EGFR, EGFR, p-AKT, AKT, p-ERK1/2 and ERK1/2 in TAZ-modulated U87 cells was measured by western blot assay. (B) The quantitative analysis of p-EGFR, p-AKT, p-ERK1/2 relative expression in TAZ-modulated U87 cells. (C) The expression of p-EGFR, EGFR, p-AKT, AKT, p-ERK1/2 and ERK1/2 in TAZ-modulated LN229 cells was measured by western blot assay. (D) The quantitative analysis of p-EGFR, p-AKT, p-ERK1/2 relative expressions in TAZ-modulated LN229 cells. (E) The expression of p-EGFR, EGFR, p-AKT, AKT, p-ERK1/2 and ERK1/2 in tumor xenografts was measured by western blot. (F) The quantitative analysis of p-EGFR, p-AKT, p-ERK1/2 relative expressions in tumor xenografts. All data are shown as the mean ± SD, *p < 0.05, **p < 0.01.